Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer

June 14, 2022 11:57 am

by Lindsey Fischer

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Patients with ovarian cancer treated with FDA-approved

Read more

First-Line Rucaparib Maintenance Improves PFS in Ovarian Cancer, Regardless of HRD Status

June 6, 2022 9:30 am

by Ariana Pelosci

The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.

Rucaparib (Rubraca) significantly improved progression-free survival

Read more

First-line Niraparib Improves PFS in Ovarian Cancer

May 18, 2022 9:16 am

by Ariana Pelosci

An individualized starting dose of niraparib, determined by weight and platelet count continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status.

An

Read more

Olaparib Dosage Can Be Reduced Without Affecting Survival in Ovarian Cancer

April 18, 2022 12:28 pm

by Lindsay Fischer

New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.

Patients with BRCA1/–mutated, platinum-sensitive, recurrent ovarian cancer who needed to reduce

Read more

Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses

April 12, 2022 1:12 pm

by Alison Kanski

NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more

Maintenance Rucaparib Significantly Improves PFS in Phase 3 ATHENA-MONO Trial for Advanced Ovarian Cancer

March 31, 2022 10:44 am

by Ariana Pelosci

A significant improvement in progression-free survival was observed in the phase 3 ATHENA-MONO trial with first-line maintenance rucaparib vs placebo in patients with advanced ovarian cancer.

Progression-free survival (PFS) was significantly improved with first-line rucaparib (Rubraca) as

Read more

Olaparib Dose Reductions/Interruptions Do Not Affect Survival in Platinum-Sensitive Ovarian Cancer

March 11, 2022 10:00 am

by Ariana Pelosci

Adverse effects associated with treatment with olaparib that led to dose reductions and interruptions did not impact survival benefit for patients with platinum-sensitive ovarian cancer.

Patients with platinum-sensitive recurrent ovarian cancer who experienced adverse effects (AEs) during

Read more

Ovarian Cancer Patients in PARP Inhibitor Trials Don’t Reflect Real-World Population

February 25, 2022 11:33 am

by Jonathan Goodman, MPhil

Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.

Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more

Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer

September 17, 2021 4:10 pm

— Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed

Patients with relapsed platinum-sensitive ovarian cancer had significant improvement in progression-free survival (PFS) when retreated with the PARP inhibitor olaparib … Read more

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumor cells

August 13, 2021 9:27 pm

A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more

Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?

July 27, 2021 12:44 pm

For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.

The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more

Ceralasertib Olaparib Combo Elicits Promising Activity In Parp Resistant Ovarian Cancer

July 15, 2021 2:43 pm

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

March 22, 2021 4:00 pm

By Chase Doyle

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more

PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status

March 22, 2021 3:00 pm

By Chase Doyle

Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more

PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

March 20, 2021 4:00 pm

Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.

By Charles Bankhead

A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.

Treatment with rucaparib (Rubraca) … Read more

How Biomarker Testing May Help Women Battling Ovarian Cancer

February 18, 2021 6:00 pm

Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.

By

Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of

Read more

PARP Inhibitors Linked With Blood Cancer Risk

December 28, 2020 11:00 am

Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden

By Leah Lawrence

Although rare, poly-ADP ribose polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and occurred even … Read more

SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

November 23, 2020 8:00 pm

By Caroline Hopkins

Using organoids that closely model certain features of ovarian tumors, researchers have identified and tested treatment combinations that may benefit patients, many of whom experience acquired or de novo resistance to PARP inhibitors.

In a study recently … Read more

The Stressful Conclusion of a Clinical Trial

November 9, 2020 9:00 am

By 

When I learned this summer that the clinical trial of the cancer drug that seems to be keeping me alive had unexpectedly shut down, I discovered the murky rules governing drug trials and the stressful confusion they … Read more